Clinical trials: Cancer Patient
Unspecified Adult Solid Tumor, Protocol Specific
GDC-0449 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as GDC-0449, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00607724
- Testing
- GDC-0449
- Volunteers
- 68 people
- Sponsor
- Genentech, Inc.
Carcinoma, Non-Small-Cell Lung
Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer
The primary objectives of this study is to assess the safety and tolerability of intravenously (i.v.) administered 186 Rhenium-isotope (186Re)-labelled bivatuzumab and to investigate the biodistribution and pharmacokinetics of…
- Trial name
- NCT02204059
- Testing
- hMAb BIWA 4
- Volunteers
- 9 people
- Sponsor
- Boehringer Ingelheim
Advanced Solid Tumors
Study of BGB-A333 Alone and in Combination With Tislelizumab in Advanced Solid Tumors
BGB-A333 is a humanized IgG1-variant monoclonal antibody against programmed cell death 1-ligand 1 (PD-L1), the ligand of an immune check point- receptor, programmed cell death-1 (PD-1).
- Trial name
- NCT03379259
- Testing
- BGB-A333, BGB-A317
- Where
- 8 sites in Australia, New Zealand and 1 more
- Volunteers
- 39 people
- Sponsor
- BeiGene
Hepatocellular Carcinoma
Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1/PD-L1 Immune Checkpoint Inhibitors
Researchers are looking for a better way to treat people diagnosed with liver cancer which may have spread to nearby tissue and is unlikely to be cured or controlled with treatment (advanced metastatic hepatocellular carcinoma…
- Trial name
- NCT04696055
- Testing
- Pembrolizumab, Regorafenib (Stivarga, BAY73-4506)
- Where
- 39 sites in United States, France and 6 more
- Volunteers
- 95 people
- Sponsor
- Bayer
Advanced Solid Tumors
AMT-676 in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase Ia/Ib study of AMT- 676, followed by an open-label, multicenter, dose-escalation.
- Trial name
- NCT06400485
- Testing
- AMT-676
- Where
- 13 sites in American Samoa, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Multitude Therapeutics Inc.
Non-Hodgkin's Lymphoma
A Study of Mitoxantrone Hydrochloride Liposome Infusion
This is a Phase 1/2, open-label, multicenter study.
- Trial name
- NCT02856685
- Testing
- Mitoxantrone Hydrochloride Liposome
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer
Phase 1b/2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer
Phase 1b/2 study to evaluate the FGFRi futibatinib in combination with the MEKi binimetinib in patients with advanced KRASmt tumors.
- Conditions
- Advanced or Metastatic Solid Tumors Irrespective of Gene Alterations, Non-Small Cell Lung Cancer, KRAS Gene Mutation
- Trial name
- NCT04965818
- Testing
- Futibatinib and Binimetinib
- Where
- 3 sites in United States
- Volunteers
- 38 people
- Sponsor
- Taiho Oncology, Inc.
Gastric Cancer, Triple Negative Breast Cancer
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
This is a a Multicenter, Open-label, Single-arm, Phase Ib Dose Escalation and Multi-cohort Expansion Clinical Study to Assess the Safety and Antitumor Activity of Niraparib in Combination with MGD013 in Patients with Advanced or…
- Conditions
- Gastric Cancer, Triple Negative Breast Cancer, Biliary Tract Carcinoma, Endometrial Carcinoma
- Trial name
- NCT04178460
- Testing
- Niraparib combined with MGD013
- Where
- 19 sites in China
- Volunteers
- 60 people
- Sponsor
- Zai Lab (Shanghai) Co., Ltd.
Neoplasm Malignant
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Primary Objective: To determine the maximum tolerated dose (MTD) of SAR442257 administered as a single agent in patients with relapsed and refractory multiple myeloma (RRMM) and relapsed and refractory non-Hodgkin lymphoma…
- Trial name
- NCT04401020
- Testing
- SAR442257
- Where
- 16 sites in United States, Czechia and 3 more
- Volunteers
- 47 people
- Sponsor
- Sanofi
Cervical Cancer
A Clinical Study of PD-L1 Antibody ZKAB001（Drug Code） in Recurrent or Metastatic Cervical Cancer
This is a Phase 1, open-label, dose-escalation, and multidose study, aiming to investigate the safety, tolerability and pharmacokinetics(PK) of ZKAB001 (a fully human monoclonal antibody targeting the Programmed Death - Ligand 1…
- Trial name
- NCT03676959
- Testing
- ZKAB001 5mg/kg, ZKAB001 10mg/kg, ZKAB001 15mg/kg
- Where
- China
- Volunteers
- 101 people
- Sponsor
- Lee's Pharmaceutical Limited
Advanced Solid Cancer
A Study of MHB046C Injection in Patients With Advanced Solid Tumors
This is a first-in-human, open-label, multicenter Phase I/II study of MHB046C in patients with advanced solid tumors. The study was designed to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of…
- Trial name
- NCT06985355
- Testing
- MHB046C
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Non-small Cell Lung Cancer
Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer
This is an open-label, multicenter, Phase 1 clinical study to evaluate the bioavailability of tislelizumab subcutaneous (SC) injection in the first-line treatment of participants with advanced or metastatic non-small cell lung…
- Trial name
- NCT06091943
- Testing
- Tislelizumab IV, Tislelizumab SC, Histology-Based Chemotherapy Doublet
- Where
- 15 sites in China, Georgia and 1 more
- Volunteers
- 62 people
- Sponsor
- BeiGene
HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms
A Safety Study of SGN-LIV1A in Breast Cancer Patients
This study will examine the safety and tolerability of ladiratuzumab vedotin (LV) in patients with metastatic breast cancer. LV will be given alone or in combination with trastuzumab.
- Conditions
- HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms, Triple Negative Breast Neoplasms, HER2 Mutations Breast Neoplasms
- Trial name
- NCT01969643
- Testing
- ladiratuzumab vedotin, Trastuzumab
- Where
- 38 sites in United States
- Volunteers
- 290 people
- Sponsor
- Seagen Inc.
Chemotherapy-induced Neutropenia
Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients
Evaluation of the efficacy and safety of recombinant human serum albumin / granulocyte-stimulating factor fusion protein for injection to prevent chemotherapy-induced neutropenia
- Trial name
- NCT03251768
- Testing
- rHSA-GCSF 2.4mg, GCSF
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Tianjin SinoBiotech Ltd.
Cancer
Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain
This is a phase III, randomized, double-blind, placebo-controlled, multicenter study of the clinical response to fentanyl sublingual spray as a treatment for breakthrough cancer pain.
- Trial name
- NCT00538850
- Testing
- Fentanyl sublingual spray
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- INSYS Therapeutics Inc
Metastatic Pancreatic Cancer, Unresectable Pancreatic Cancer
BP-C1 in Short-term Treatment of Metastatic Pancreatic Cancer
The aim of this study is to investigate the short-term effect and tolerability BP-C1 in patients with metastatic pancreatic cancer who has undergone guideline-recommended chemotherapy.
- Trial name
- NCT03627390
- Testing
- BP-C1, BP-C2
- Where
- Egypt
- Volunteers
- 16 people
- Sponsor
- Meabco A/S
Lymphoma, Advanced Solid Tumors
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-02)
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma.
- Trial name
- NCT00520390
- Testing
- EZN-2208
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Enzon Pharmaceuticals, Inc.
Biliary Tract or Colorectal Cancer With Her2-positive/Mutated
A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.
To evaluate the efficacy and safety of SPH5030 tablets in subjects with Her2-positive/mutated biliary tract OR colorectal cancer.
- Trial name
- NCT06434597
- Testing
- SPH5030
- Where
- 30 sites in China
- Volunteers
- 60 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Advanced or Metastatic NSCLC
A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy
A study to investigate efficacy and safety of ceralasertib plus durvalumab in participants aged ≥ 18 years with advanced or metastatic non-small cell lung cancer whose disease progressed on or after prior anti-PD-(L)1 therapy and…
- Trial name
- LOTOS (NCT05941897)
- Testing
- Ceralasertib, Durvalumab
- Where
- 8 sites in Russia
- Volunteers
- 39 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Squamous Cell Carcinoma
Study of Addition of Panitumumab to Chemoradiation Therapy in Patients With Locally Advanced Head and Neck Cancer
The addition of chemotherapy to radiotherapy (chemoradiation) has improved outcomes for patients with locally advanced squamous cell carcinoma of the head and neck but additional improvements to treatment regimens are needed.
- Trial name
- NCT00500760
- Testing
- Cisplatin, Standard Fractionation Radiotherapy, Panitumumab
- Volunteers
- 153 people
- Sponsor
- Amgen
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.